Pfizer Inc. (PFE) Position Reduced by Warren Averett Asset Management LLC

Warren Averett Asset Management LLC trimmed its position in shares of Pfizer Inc. (NYSE:PFE) by 12.8% during the 3rd quarter, according to its most recent 13F filing with the SEC. The fund owned 26,458 shares of the biopharmaceutical company’s stock after selling 3,869 shares during the quarter. Warren Averett Asset Management LLC’s holdings in Pfizer were worth $945,000 at the end of the most recent reporting period.

Other hedge funds have also recently made changes to their positions in the company. Shine Investment Advisory Services Inc. bought a new position in Pfizer during the 2nd quarter valued at about $102,000. Mckinley Capital Management LLC Delaware bought a new position in Pfizer during the 2nd quarter valued at about $103,000. D. Scott Neal Inc. lifted its stake in Pfizer by 19.3% during the 2nd quarter. D. Scott Neal Inc. now owns 3,112 shares of the biopharmaceutical company’s stock valued at $105,000 after acquiring an additional 504 shares during the period. Herndon Capital Management LLC bought a new position in Pfizer during the 2nd quarter valued at about $120,000. Finally, Private Vista LLC lifted its stake in Pfizer by 2,277.3% during the 2nd quarter. Private Vista LLC now owns 199,317 shares of the biopharmaceutical company’s stock valued at $133,000 after acquiring an additional 190,933 shares during the period. 69.74% of the stock is currently owned by institutional investors.

Shares of Pfizer Inc. (NYSE:PFE) opened at $36.47 on Thursday. Pfizer Inc. has a one year low of $30.90 and a one year high of $37.35. The company has a market cap of $217,390.00, a P/E ratio of 22.37, a price-to-earnings-growth ratio of 2.46 and a beta of 1.01. The company has a current ratio of 1.43, a quick ratio of 1.15 and a debt-to-equity ratio of 0.56.

Pfizer (NYSE:PFE) last released its earnings results on Tuesday, October 31st. The biopharmaceutical company reported $0.67 EPS for the quarter, topping analysts’ consensus estimates of $0.65 by $0.02. Pfizer had a net margin of 18.69% and a return on equity of 25.41%. The company had revenue of $13.17 billion for the quarter, compared to analysts’ expectations of $13.17 billion. During the same quarter last year, the business earned $0.61 EPS. The firm’s revenue was up .9% compared to the same quarter last year. equities analysts forecast that Pfizer Inc. will post 2.59 earnings per share for the current year.

Pfizer announced that its Board of Directors has initiated a share repurchase plan on Monday, December 18th that authorizes the company to buyback $10.00 billion in shares. This buyback authorization authorizes the biopharmaceutical company to repurchase shares of its stock through open market purchases. Shares buyback plans are generally an indication that the company’s board of directors believes its stock is undervalued.

The company also recently announced a quarterly dividend, which will be paid on Thursday, March 1st. Shareholders of record on Friday, February 2nd will be paid a dividend of $0.34 per share. This is a boost from Pfizer’s previous quarterly dividend of $0.32. The ex-dividend date is Thursday, February 1st. This represents a $1.36 dividend on an annualized basis and a yield of 3.73%. Pfizer’s dividend payout ratio (DPR) is presently 78.53%.

In other Pfizer news, insider Alexander R. Mackenzie sold 6,750 shares of the stock in a transaction that occurred on Friday, December 15th. The shares were sold at an average price of $37.00, for a total transaction of $249,750.00. Following the completion of the sale, the insider now directly owns 103,458 shares of the company’s stock, valued at approximately $3,827,946. The sale was disclosed in a legal filing with the SEC, which is available at this link. Also, EVP Rady A. Johnson sold 8,000 shares of the stock in a transaction that occurred on Friday, December 15th. The shares were sold at an average price of $37.07, for a total transaction of $296,560.00. Following the sale, the executive vice president now directly owns 46,963 shares of the company’s stock, valued at $1,740,918.41. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 29,450 shares of company stock worth $1,065,220. 0.06% of the stock is owned by company insiders.

Several equities analysts have issued reports on PFE shares. BMO Capital Markets set a $37.00 target price on shares of Pfizer and gave the company a “buy” rating in a research note on Tuesday, October 10th. ValuEngine upgraded shares of Pfizer from a “hold” rating to a “buy” rating in a research note on Friday, October 6th. Zacks Investment Research cut shares of Pfizer from a “buy” rating to a “hold” rating in a research note on Wednesday, October 11th. Deutsche Bank set a $38.00 price objective on shares of Pfizer and gave the stock a “buy” rating in a research note on Wednesday, October 11th. Finally, Morgan Stanley upgraded shares of Pfizer from an “equal weight” rating to an “overweight” rating and increased their price objective for the stock from $35.00 to $39.00 in a research note on Wednesday, September 20th. Two research analysts have rated the stock with a sell rating, seven have assigned a hold rating and thirteen have assigned a buy rating to the company’s stock. The company has an average rating of “Buy” and a consensus price target of $38.83.

TRADEMARK VIOLATION NOTICE: This piece of content was published by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are viewing this piece of content on another site, it was stolen and republished in violation of U.S. and international copyright legislation. The legal version of this piece of content can be viewed at https://www.dispatchtribunal.com/2018/01/11/pfizer-inc-pfe-position-reduced-by-warren-averett-asset-management-llc.html.

About Pfizer

Pfizer Inc (Pfizer) is a research-based global biopharmaceutical company. The Company is engaged in the discovery, development and manufacture of healthcare products. Its global portfolio includes medicines and vaccines, as well as consumer healthcare products. The Company manages its commercial operations through two business segments: Pfizer Innovative Health (IH) and Pfizer Essential Health (EH).

Want to see what other hedge funds are holding PFE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Pfizer Inc. (NYSE:PFE).

Institutional Ownership by Quarter for Pfizer (NYSE:PFE)

Receive News & Ratings for Pfizer Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pfizer and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply